查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1950521

PD-1/PD-L1查核點抑制劑市場按產品、治療線、適應症、最終用戶和分銷管道分類，全球預測，2026-2032 年

PD-1/PD-L1 Checkpoint Inhibitors Market by Product, Line Of Therapy, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 PD-1/PD-L1查核點抑制劑市場在 2025 年的價值為 577.7 億美元，在 2026 年成長至 595.3 億美元，複合年成長率為 5.81%，到 2032 年將達到 858.3 億美元。

關鍵市場統計數據
基準年 2025 577.7億美元
預計年份：2026年 595.3億美元
預測年份 2032 858.3億美元
複合年成長率 (%) 5.81%

本文概述了PD-1/PD-L1查核點抑制劑如何重塑腫瘤治療、臨床決策流程以及整個醫療保健系統相關人員的優先事項。

PD-1/PD-L1查核點抑制劑透過活化免疫系統，在多種腫瘤類型中產生持久療效，徹底改變了腫瘤治療的模式。自臨床應用以來，這些藥物已將臨床思路從單純的細胞毒性治療轉向以免疫調節為導向的策略，旨在長期控制疾病、提高生存率，同時平衡毒性和患者生活品質。這類藥物包括單株抗體，它們能夠阻斷程序性死亡蛋白1（PD-1）與其配體之間的抑制性訊號傳導，從而重新活化抗腫瘤T細胞的活性。

科學發現的融合、適應性試驗設計的改進以及以價值主導的商業策略，正在從根本上重塑PD-1/PD-L1抑制劑的競爭格局和臨床應用。

PD-1/PD-L1查核點抑制劑領域正經歷由科學、臨床和商業性動態融合驅動的變革，重塑競爭優勢和臨床效用的定義。轉化科學的進步已將生物標記的發現從PD-L1表達擴展到包括腫瘤突變負荷、新抗原譜和聯合免疫特徵，從而更準確地預測治療反應並指南個體化治療方案的選擇。這些進展正在加速免疫療法進入早期治療階段，同時也有助於開發克服原發性和後天抗藥性的聯合治療策略。

評估2025年關稅政策變化將對生物製藥供應鏈造成的營運壓力，以及策略採購轉型、韌性投資和准入風險緩解措施的必要性。

2025年實施的新關稅和貿易政策調整顯著增加了生物製藥（包括PD-1/PD-L1查核點抑制劑）全球供應鏈相關人員的營運複雜性。生物製藥的生產高度專業化，依賴原料、一次性技術、質體和專用耗材的跨境流通。進口原料關稅導致成本上升，增加了生產費用，並促使企業重新審視籌資策略和供應商合約。生物製藥尤其容易受到供應鏈中斷的影響，因為其生產前置作業時間長，且需要檢驗的品質體系，而供應鏈中斷可能會對產品供應和庫存管理產生連鎖反應。

可操作的細分洞察，揭示產品屬性、適應症證據、臨床物流、治療線定位和分銷管道如何影響市場採納趨勢。

細分市場層面的趨勢分析揭示了關鍵產品、適應症、終端用戶、治療方案和分銷管道等各個維度上的差異化機會和營運考慮。在產品層面，Atezolizumab、西米普利單抗、Durvalumab、納武利尤Nivolumab和Pembrolizumab等藥物因其給​​藥方案、安全性特徵和核准的適應症而具有獨特的臨床差異，這些差異影響著醫生的處方行為，並支撐著每種藥物的生命週期策略。從適應症層面來看，何傑金氏淋巴瘤、黑色素瘤、非小細胞肺癌、腎細胞癌和尿路上皮癌的治療結果和臨床試驗過程構成了多元化的證據基礎，影響著指引的納入和病患選擇標準。

比較美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和進入挑戰，以確定優先採用途徑和政策參與方式

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床應用、監管路徑和商業性發展產生了顯著影響，每個地區都有其獨特的結構性和政策因素影響PD-1/PD-L1療法的可及性。在美洲，監管的一致性和強大的臨床試驗基礎設施歷來支持快速產生證據和早期獲得多種適應症的治療。同時，支付方體係也越來越重視以療效為基礎的合約和管理式引進許可安排。這導致在醫院和專科機構中，實際療效和價格效益等因素會影響處方集的納入和使用。

採取具有競爭力和策略性的企業行動，重點關注臨床拓展、診斷夥伴關係、供應鏈多元化和患者權益倡導，以確保永續的商業性地位。

主要企業的洞察凸顯了製造商和研發合作夥伴如何透過投資拓展臨床應用範圍、建立策略聯盟以及提供以患者為中心的服務來實現差異化。各公司優先進行註冊試驗和探索性試驗，評估適應症擴展以及針對關鍵抗藥性機制的合理聯合治療。與診斷公司和研究機構建立策略聯盟，能夠共同開發伴隨診斷和聯合生物標記策略，從而最佳化患者選擇，並增強對臨床醫生和支付方的價值提案。

為高階主管提供具體策略建議，以加速臨床差異化，確保穩健的價值鏈，並向複雜的腫瘤系統內的支付方展現相關價值。

希望在PD-1/PD-L1抑制劑領域鞏固地位的行業領導者應採取一系列有計劃且切實可行的步驟，將科學創新與業務永續營運可行性和市場進入要求相結合。首先，應優先發展以生物標記主導的研發，並投資於轉化研究和診斷夥伴關係，以實現精準的患者篩選，並增強與臨床醫生和支付方溝通的價值。這種方法有助於更有效率的臨床試驗設計，加速識別有效族群，降低研發風險，並提高臨床效益的清晰度。

採用透明的混合調查方法，結合臨床證據審查、相關人員訪談和三角驗證的二手資料分析，確保得出可靠且可操作的分析結果。

本研究採用混合方法：系統性文獻綜述、與關鍵相關人員的直接訪談以及二手資料的三角驗證，以確保分析的全面性和方法的嚴謹性。文獻綜述涵蓋了同行評審的臨床研究、監管文件和政策相關出版物，並用於梳理治療適應症、安全性概況和試驗結果。主要研究包括對臨床醫生、供應鏈專業人員和支付方代表進行結構化訪談，以了解他們對PD-1/PD-L1療法的使用模式、准入障礙和營運限制等方面的實地觀點。

簡要概述強調了PD-1/PD-L1療法持續重要的臨床意義，以及製定綜合策略以維持其可及性和價值的必要性。

PD-1/PD-L1查核點抑制劑是現代腫瘤學的基石，能夠帶來顯著的臨床益處，並推動治療順序、聯合治療和生物標記主導醫學等新模式的出現。隨著轉化科學的進步、適應性調查方法的改進以及對真實世界療效的日益關注，這類治療藥物的臨床應用範圍和複雜性也在擴大。從研發、生產、分銷到臨床實踐的各個環節，相關人員必須在快速創新與務實措施之間取得平衡，以確保患者能夠獲得充足的治療，並持續創造價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. PD-1/PD-L1查核點抑制劑市場（依產品分類）

  • Atezolizumab
  • 塞米普利單抗
  • Durvalumab
  • Nivolumab
  • Pembrolizumab

9. 依治療領域分類的PD-1/PD-L1查核點抑制劑市場

  • 主要治療
  • 四線治療及以後
  • 二級治療
  • 三級治療

第10章：PD-1/PD-L1查核點抑制劑市場（依適應症分類）

  • 何傑金氏淋巴瘤
  • 惡性黑色素瘤
  • 非小細胞肺癌
  • 腎臟細胞癌
  • 尿路上皮癌

第11章：依最終用戶分類的PD-1/PD-L1查核點抑制劑市場

  • 門診手術中心
  • 癌症中心
  • 醫院藥房
  • 零售藥房

12. PD-1/PD-L1查核點抑制劑市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 專科藥房

13. PD-1/PD-L1查核點抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：PD-1/PD-L1查核點抑制劑市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國PD-1/PD-L1查核點抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國：PD-1/PD-L1查核點抑制劑市場

17. 中國：PD-1/PD-L1查核點抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus Inc.
  • Akeso, Inc.
  • Arcus Biosciences, Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Biocad JSC
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CStone Pharmaceuticals Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Incyte Corporation
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Seagen Inc.
  • Shanghai Henlius Biotech, Inc.
  • Shanghai Junshi Bioscience Co., Ltd.
Product Code: MRR-4F7A6D4FD8B8

The PD-1/PD-L1 Checkpoint Inhibitors Market was valued at USD 57.77 billion in 2025 and is projected to grow to USD 59.53 billion in 2026, with a CAGR of 5.81%, reaching USD 85.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 57.77 billion
Estimated Year [2026] USD 59.53 billion
Forecast Year [2032] USD 85.83 billion
CAGR (%) 5.81%

A strategic overview describing how PD-1/PD-L1 checkpoint inhibitors reshaped oncology care, clinical decision pathways, and stakeholder priorities across healthcare systems

PD-1/PD-L1 checkpoint inhibitors have transformed oncology treatment paradigms by harnessing the immune system to deliver durable responses across a range of tumor types. Since their clinical emergence, these agents have shifted clinical thinking from cytotoxic-only approaches to immunomodulatory strategies that seek long-term disease control and improved survival while recalibrating toxicity profiles and patient quality of life. As a class, they encompass monoclonal antibodies that block inhibitory signals between programmed cell death protein 1 and its ligand, thereby reinvigorating antitumor T cell activity.

The therapeutic significance of these agents extends beyond single-agent activity to their integration into multi-modal regimens, including combinations with targeted therapies, chemotherapy, and radiation. Their adoption has been driven by robust clinical trial programs that validated efficacy in historically hard-to-treat indications, and by guideline updates that broadened eligibility for earlier lines of therapy. In parallel, healthcare systems and clinicians have adjusted pathways to accommodate new administration patterns, toxicity management protocols, and molecular diagnostics that guide patient selection.

From a commercial and strategic perspective, stakeholders face a dynamic landscape where clinical evidence, regulatory decisions, and competitive differentiation interact. Payers and providers are developing value frameworks to manage access and reimbursement, while manufacturers pursue label expansions and lifecycle management strategies to sustain therapeutic relevance. Collectively, these forces shape investment priorities, R&D focus, and distribution approaches across the PD-1/PD-L1 inhibitor ecosystem.

How converging scientific discoveries, adaptive trial designs, and value-driven commercial strategies are fundamentally reshaping the PD-1/PD-L1 inhibitor competitive landscape and clinical adoption

The landscape for PD-1/PD-L1 checkpoint inhibition is undergoing transformative shifts driven by converging scientific, clinical, and commercial dynamics that redefine competitive advantage and clinical utility. Advances in translational science are refining biomarker discovery beyond PD-L1 expression to include tumor mutational burden, neoantigen landscapes, and composite immune signatures that more accurately predict response and guide personalized treatment selection. These developments have accelerated the movement of immunotherapy into earlier lines of care while informing combination strategies intended to overcome primary and acquired resistance.

Clinical trial design has evolved to test adaptive and platform approaches, enabling more efficient evaluation of combination regimens and biomarker-driven cohorts. This has led to a faster cycle of evidence generation, permitting label expansions and niche indications to be pursued in parallel with broader registrational programs. Simultaneously, real-world evidence initiatives are maturing and providing complementary insights into long-term safety, effectiveness in diverse patient populations, and utilization patterns across different care settings.

On the commercial front, differentiation is increasingly achieved through safety and tolerability profiles, convenience of administration, and demonstrated value propositions that resonate with payers and clinicians. Manufacturers are investing in patient support programs, diagnostics partnerships, and digital tools to optimize adherence and outcomes. These shifts collectively create an environment where agility in clinical development, clarity in value demonstration, and collaboration across clinical, payer, and diagnostic stakeholders determine sustainable success.

An assessment of how 2025 tariff policy changes exert operational pressure on biologics supply chains, prompting strategic sourcing shifts, resilience investments, and access risk mitigation

The introduction of new tariff measures and trade policy shifts in 2025 has added a material layer of operational complexity for stakeholders involved in the global supply chains of biologic therapies, including PD-1/PD-L1 checkpoint inhibitors. Biologic manufacturing is highly specialized and dependent on cross-border flows of raw materials, single-use technologies, plasmids, and specialized consumables. Any tariff-induced increases in the cost of imported inputs can lead to incremental manufacturing expenses, prompting reassessment of sourcing strategies and supplier contracts. Importantly, biologics are sensitive to supply chain discontinuities because of long lead times for production and the need for validated quality systems, so disruptions can have cascading effects on product availability and inventory management.

In response to tariff pressures, manufacturers and contract development and manufacturing organizations have been evaluating nearshoring, dual sourcing, and vertical integration strategies to mitigate exposure. These strategic responses can reduce reliance on affected trade corridors but often require capital investment and extended qualification timelines. Payers and providers, meanwhile, are focused on continuity of care; therefore, interruptions to supply or shifts in distribution economics can prompt changes in formulary decisions and operational workflows for hospital pharmacies and specialty distributors.

Regulatory authorities and industry groups have emphasized the need for transparency and contingency planning to safeguard patient access. Collaboration between regulators, manufacturers, and logistics providers has become more urgent to ensure that quality-assured therapies remain available and that cost pressures do not erode the clinical gains realized with PD-1/PD-L1 therapies. Ultimately, the cumulative impact of tariff changes reinforces the importance of resilient supply chain design, diversified supplier networks, and proactive stakeholder engagement to preserve therapeutic continuity and protect patient outcomes.

Actionable segmentation insights revealing how product attributes, indication evidence, care setting logistics, therapy line positioning, and distribution channels shape adoption dynamics

Segment-level dynamics reveal differentiated opportunities and operational considerations across key product, indication, end user, line of therapy, and distribution channel dimensions. Within the product dimension, agents such as Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, and Pembrolizumab each present distinct clinical differentiators related to dosing schedules, safety profiles, and approved indications, which shape physician prescribing behavior and support distinct lifecycle strategies. Transitioning to the indication lens, therapeutic performance and clinical trial history in Hodgkin Lymphoma, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma create varied evidence backdrops that influence guideline inclusion and patient selection criteria.

End user considerations span ambulatory surgical centers, cancer specialty centers, hospital pharmacies, and retail pharmacies, and each setting has unique operational workflows, cold chain requirements, and reimbursement environments that determine where and how PD-1/PD-L1 therapies are administered. Line of therapy distinctions between first line, second line, third line, and fourth line and beyond drive different clinical expectations for response durability, combination regimens, and supportive care needs, which in turn inform clinical development priorities and commercial messaging. Distribution channel realities involving hospital pharmacy, online pharmacy, and specialty pharmacy models also affect access pathways, patient support services, and the feasibility of home-based administration programs.

Taken together, these segmentation dimensions require integrated strategies that align clinical development with distribution capabilities and provider preferences. Manufacturers and service providers must tailor value propositions to the specific constellation of product attributes, indication-level evidence, care setting constraints, and patient journey considerations to maximize therapeutic uptake and ensure sustainable delivery of care.

Comparative regional dynamics and access challenges across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and policy engagement priorities

Regional dynamics exert a pronounced influence on clinical adoption, regulatory pathways, and commercial execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct structural and policy factors that shape access to PD-1/PD-L1 therapies. In the Americas, regulatory alignment and strong clinical trial infrastructures have historically supported rapid evidence generation and earlier access in many indications, while payer systems are increasingly focused on outcomes-based contracting and managed entry agreements. This creates an environment where demonstrable real-world benefit and price-performance considerations influence formulary positioning and utilization in hospital and specialty settings.

In Europe, Middle East & Africa, heterogeneity in national reimbursement frameworks and pricing policies requires tailored market access strategies, including early engagement with health technology assessment bodies and the development of country-specific value dossiers. Stakeholders in this region must navigate diverse procurement mechanisms and varying levels of infrastructure for complex biologic administration. Conversely, the Asia-Pacific region offers a combination of rapidly expanding oncology care capacity and a strong emphasis on local manufacturing and partnerships, which can accelerate adoption when regulatory pathways and pricing strategies are aligned with national health priorities. Across all regions, local data generation, collaborative payer dialogues, and investments in diagnostics and patient support services are essential to translating clinical efficacy into sustainable access and meaningful patient outcomes.

Strategic stakeholders should therefore design region-specific approaches that account for regulatory timing, reimbursement frameworks, and health system capacity, while leveraging cross-border learnings to inform global launch sequencing and post-authorization evidence generation.

Competitive and strategic company actions that emphasize clinical expansion, diagnostic partnerships, supply diversification, and patient support to secure durable commercial positions

Key company insights center on how manufacturers and development partners are differentiating through clinical breadth, strategic collaborations, and investments in patient-centric services. Firms are prioritizing registrational and exploratory trials that expand indications and evaluate rational combinations to address primary resistance mechanisms. Strategic alliances with diagnostic companies and research institutions are enabling co-development of companion diagnostics and composite biomarker strategies that refine patient selection and strengthen value propositions to clinicians and payers.

Commercial differentiation increasingly relies on holistic patient support ecosystems that encompass adherence programs, reimbursement navigation, and digital health tools to monitor outcomes and manage adverse events. Contract manufacturing and contract development partners play a critical role in scaling supply while enabling geographic diversification of production. Mergers, acquisitions, and licensing agreements remain common mechanisms for augmenting portfolios and accelerating access to novel science or geographic footprints. Additionally, companies are engaging in sophisticated real-world evidence programs to complement clinical trial data, validate long-term safety and effectiveness, and support conversations with health technology assessment bodies.

For industry participants, the combination of robust clinical pipelines, disciplined manufacturing strategies, and multi-stakeholder engagement capabilities will determine which organizations can most effectively translate scientific innovation into sustained therapeutic reach and commercial resilience.

Practical strategic recommendations for senior leaders to accelerate clinical differentiation, secure resilient supply chains, and demonstrate payer-relevant value across complex oncology systems

Industry leaders seeking to strengthen their position in the PD-1/PD-L1 inhibitor space should pursue a set of deliberate, actionable steps that align scientific innovation with operational resilience and market access imperatives. First, prioritize biomarker-driven development by investing in translational research and diagnostics partnerships that enable precise patient selection and enhance value communication to clinicians and payers. This approach supports more efficient trial designs and can accelerate the identification of responder populations, reducing development risk and improving the clarity of clinical benefit.

Second, build supply chain resilience through diversified sourcing, strategic partnerships with contract manufacturers, and scenario planning for trade-policy volatility. Investing in manufacturing redundancy and qualifying alternative suppliers for critical biologic inputs will reduce supply disruptions and preserve patient access. Third, design differentiated patient support and reimbursement navigation programs that lower barriers to initiation and continuation of therapy, while collecting real-world evidence that reinforces clinical value and supports payer negotiations. Fourth, pursue adaptive and pragmatic clinical trial designs that generate timely evidence for label expansion and real-world performance, enabling more rapid translation of promising combinations into standard-of-care options.

Finally, engage proactively with payers, regulators, and provider networks to co-create value frameworks and reimbursement models that reward long-term outcomes. By aligning development strategies with health system priorities and demonstrating measurable patient benefit, leaders can secure durable access and sustain commercial momentum in a rapidly evolving immuno-oncology landscape.

A transparent mixed-methods research approach combining clinical evidence review, stakeholder interviews, and triangulated secondary data to ensure robust, actionable analysis

This research employed a mixed-methods approach combining systematic literature synthesis, primary stakeholder interviews, and secondary data triangulation to ensure comprehensive analysis and methodological rigor. The literature synthesis included peer-reviewed clinical studies, regulatory documents, and policy publications, which were used to map therapeutic indications, safety profiles, and trial outcomes. Primary research involved structured interviews with clinicians, supply chain experts, and payer representatives to capture front-line perspectives on utilization patterns, access barriers, and operational constraints relevant to PD-1/PD-L1 therapies.

Secondary data sources consisted of clinical trial registries, regulatory approval announcements, and real-world evidence studies that were cross-validated to ensure consistency. Analytical frameworks emphasized segmentation by product attributes, indication-specific clinical dynamics, care setting logistics, and distribution channel implications. Scenario analysis was applied to assess potential operational impacts of external pressures such as trade policy changes and supply chain disruptions, while sensitivity checks were used to test the robustness of qualitative inferences.

Quality assurance processes included independent peer review of key findings, reconciliation of conflicting evidence through expert consultation, and clear documentation of data sources and methodological assumptions. The result is an evidence-informed synthesis designed to support strategic decision-making while maintaining transparency about analytical boundaries and the evolving nature of clinical and regulatory developments in immuno-oncology.

A concise synthesis emphasizing the enduring clinical importance of PD-1/PD-L1 therapies and the imperative for integrated strategies that preserve access and sustain value

PD-1/PD-L1 checkpoint inhibitors represent a foundational pillar of modern oncology, delivering substantive clinical benefits and catalyzing new paradigms in treatment sequencing, combination therapy, and biomarker-driven care. The therapeutic class continues to expand in clinical scope and complexity, shaped by advances in translational science, adaptive trial methodologies, and an intensified focus on real-world outcomes. Stakeholders operating across development, manufacturing, distribution, and clinical practice must therefore balance rapid innovation with pragmatic measures to ensure resilient access and sustained value delivery to patients.

The interplay of regional reimbursement regimes, evolving payer expectations, and external operational pressures such as trade policy changes underscores the need for integrated strategies that align evidence generation with supply chain robustness and tailored market access plans. Companies that invest in diagnostic partnerships, diversified manufacturing footprints, and comprehensive patient support models will be best positioned to translate scientific breakthroughs into durable clinical and commercial impact. Equally, healthcare systems and payers will need to refine value frameworks that reward meaningful long-term outcomes and support equitable patient access.

In sum, the PD-1/PD-L1 inhibitor landscape is a dynamic arena where scientific promise and operational discipline must coalesce to sustain progress and improve patient outcomes across diverse oncology settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PD-1/PD-L1 Checkpoint Inhibitors Market, by Product

  • 8.1. Atezolizumab
  • 8.2. Cemiplimab
  • 8.3. Durvalumab
  • 8.4. Nivolumab
  • 8.5. Pembrolizumab

9. PD-1/PD-L1 Checkpoint Inhibitors Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Fourth Line And Beyond
  • 9.3. Second Line
  • 9.4. Third Line

10. PD-1/PD-L1 Checkpoint Inhibitors Market, by Indication

  • 10.1. Hodgkin Lymphoma
  • 10.2. Melanoma
  • 10.3. Non Small Cell Lung Cancer
  • 10.4. Renal Cell Carcinoma
  • 10.5. Urothelial Carcinoma

11. PD-1/PD-L1 Checkpoint Inhibitors Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Cancer Specialty Center
  • 11.3. Hospital Pharmacy
  • 11.4. Retail Pharmacy

12. PD-1/PD-L1 Checkpoint Inhibitors Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Specialty Pharmacy

13. PD-1/PD-L1 Checkpoint Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. PD-1/PD-L1 Checkpoint Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. PD-1/PD-L1 Checkpoint Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States PD-1/PD-L1 Checkpoint Inhibitors Market

17. China PD-1/PD-L1 Checkpoint Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agenus Inc.
  • 18.6. Akeso, Inc.
  • 18.7. Arcus Biosciences, Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. BeiGene Ltd.
  • 18.10. Biocad JSC
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Celldex Therapeutics, Inc.
  • 18.13. CStone Pharmaceuticals Co., Ltd.
  • 18.14. Eli Lilly and Company
  • 18.15. F. Hoffmann-La Roche Ltd
  • 18.16. Genentech, Inc.
  • 18.17. Incyte Corporation
  • 18.18. Jiangsu Hengrui Medicine Co., Ltd.
  • 18.19. Merck & Co., Inc.
  • 18.20. Merck KGaA
  • 18.21. Novartis AG
  • 18.22. Ono Pharmaceutical Co., Ltd.
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Seagen Inc.
  • 18.27. Shanghai Henlius Biotech, Inc.
  • 18.28. Shanghai Junshi Bioscience Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY UROTHELIAL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY UROTHELIAL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY UROTHELIAL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA PD-1/PD-L1 CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)